Table 2.
Use of lipid-lowering therapy.
| Lipid-lowering therapy, n (%) | LLT at enrolmenta |
Stabilized LLTb |
||
|---|---|---|---|---|
| Germany N = 421 |
Overall [20] N = 5888 |
Germany N = 327 |
Overall [20] N = 4112 |
|
| Any LLTc | ||||
| Any statin | 394 (93.6) | 5554 (94.3) | 305 (93.3) | 3856 (93.8) |
| High-intensity statin | 89 (21.1) | 2028 (34.4) | 72 (22.0) | 1306 (31.8) |
| Moderate-intensity statin | 239 (56.8) | 3164 (53.7) | 177 (54.1) | 2279 (55.4) |
| Low-intensity statin | 34 (8.1) | 226 (3.8) | 28 (8.6) | 171 (4.2) |
| Unknown intensity statin | 32 (7.6) | 136 (2.3) | 28 (8.6) | 100 (2.4) |
| Ezetimibe | 87 (20.7) | 667 (11.3) | 78 (23.9) | 491 (11.9) |
| PCSK9 antibody | 14 (3.3) | 81 (1.4) | 12 (3.7) | 59 (1.4) |
| Fibrates | 16 (3.8) | 248 (4.2) | 15 (4.6) | 181 (4.4) |
| Fish oils | 23 (5.5) | 43 (0.7) | 20 (6.1) | 36 (0.9) |
| Other | 3 (0.7) | 16 (0.3) | 3 (0.9) | 12 (0.3) |
| All LLTd | ||||
| Statin monotherapy | ||||
| High-intensity statin monotherapy | 69 (16.4) | 1787 (30.3) | 53 (16.2) | 1134 (27.6) |
| Moderate-intensity statin monotherapy | 220 (52.3) | 2966 (50.4) | 160 (48.9) | 2131 (51.8) |
| Low-intensity statin monotherapy | 29 (6.9) | 194 (3.3) | 24 (7.3) | 148 (3.6) |
| Ezetimibe combination | 65 (15.4) | 516 (8.8) | 58 (17.7) | 380 (9.2) |
| PCSK9 antibody combination | 10 (2.4) | 64 (1.1) | 9 (2.8) | 49 (1.2) |
| Other | 28 (6.7) | 361 (6.1) | 23 (7.0) | 270 (6.6) |
LLT = lipid-lowering therapy; PCSK9 = proprotein convertase subtilisin/kexin type 9.
Fibrates: bezafibrate, clofibrate, ciprofibrate, clofibride, clinofibrate, gemfibrozil, etofibrate, fenofibrate, ronifibrate, simfibrate.
Statin intensity was defined per the American College of Cardiology/American Heart Association definition [32].
a
Use of LLT continuing at enrolment.
b
Use of LLT at the time of LDL-C measurement where LLT is stabilized (no change in LLT dose or regimen for at least 28 days prior to the LDL-C measurement date) for those patients evaluable for goal attainment.
c
Any use of a specific LLT regardless of whether a patient also received any other LLT.
d
All LLT used by each patient.